Atara Biotherapeutics Inc (ATRA) CEO Isaac E. Ciechanover Sells 19,300 Shares

Atara Biotherapeutics Inc (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 19,300 shares of the company’s stock in a transaction that occurred on Friday, January 26th. The stock was sold at an average price of $35.26, for a total transaction of $680,518.00. Following the sale, the chief executive officer now directly owns 743,675 shares in the company, valued at $26,221,980.50. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Shares of Atara Biotherapeutics Inc (NASDAQ ATRA) remained flat at $$37.25 during trading hours on Monday. 1,209,742 shares of the company traded hands, compared to its average volume of 1,429,886. Atara Biotherapeutics Inc has a 1 year low of $11.80 and a 1 year high of $39.65. The company has a market capitalization of $1,400.45, a PE ratio of -10.73 and a beta of 1.27.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($1.02) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.97) by ($0.05). analysts expect that Atara Biotherapeutics Inc will post -4 earnings per share for the current year.

Several large investors have recently made changes to their positions in the business. Dimensional Fund Advisors LP increased its position in shares of Atara Biotherapeutics by 2.9% in the 2nd quarter. Dimensional Fund Advisors LP now owns 21,718 shares of the biotechnology company’s stock valued at $304,000 after purchasing an additional 610 shares during the last quarter. Teachers Advisors LLC boosted its holdings in shares of Atara Biotherapeutics by 2.4% in the 2nd quarter. Teachers Advisors LLC now owns 47,156 shares of the biotechnology company’s stock valued at $660,000 after buying an additional 1,110 shares in the last quarter. The Manufacturers Life Insurance Company boosted its holdings in shares of Atara Biotherapeutics by 7.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 20,377 shares of the biotechnology company’s stock valued at $285,000 after buying an additional 1,369 shares in the last quarter. Voya Investment Management LLC boosted its holdings in shares of Atara Biotherapeutics by 16.2% in the 2nd quarter. Voya Investment Management LLC now owns 11,813 shares of the biotechnology company’s stock valued at $165,000 after buying an additional 1,651 shares in the last quarter. Finally, Rhumbline Advisers boosted its holdings in shares of Atara Biotherapeutics by 11.3% in the 2nd quarter. Rhumbline Advisers now owns 31,373 shares of the biotechnology company’s stock valued at $439,000 after buying an additional 3,175 shares in the last quarter. 69.71% of the stock is currently owned by institutional investors.

Several equities research analysts recently weighed in on the stock. Cowen assumed coverage on shares of Atara Biotherapeutics in a research note on Friday. They set an “outperform” rating on the stock. BidaskClub raised shares of Atara Biotherapeutics from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, January 23rd. Canaccord Genuity reissued a “positive” rating and issued a $70.00 price objective (up from $47.00) on shares of Atara Biotherapeutics in a research report on Friday, January 19th. Citigroup raised shares of Atara Biotherapeutics from a “sell” rating to a “neutral” rating and set a $18.00 price objective on the stock in a research report on Wednesday, January 3rd. Finally, ValuEngine raised shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Friday, December 29th. Four equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. Atara Biotherapeutics currently has a consensus rating of “Buy” and an average target price of $30.60.

COPYRIGHT VIOLATION WARNING: “Atara Biotherapeutics Inc (ATRA) CEO Isaac E. Ciechanover Sells 19,300 Shares” was originally published by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://www.americanbankingnews.com/2018/01/29/atara-biotherapeutics-inc-atra-ceo-isaac-e-ciechanover-sells-19300-shares.html.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply